{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:32:43Z","timestamp":1773660763401,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alcoholism Clin &amp; Exp Res"],"published-print":{"date-parts":[[2016,4]]},"abstract":"Background<\/jats:title>ABT<\/jats:styled-content>\u2010436, a potent and selective arginine vasopressin (AVP<\/jats:styled-content>) type 1B<\/jats:styled-content> receptor (V<\/jats:styled-content>1B<\/jats:sub>) antagonist, has previously demonstrated basal hypothalamic\u2013pituitary\u2013adrenal (HPA<\/jats:styled-content>) axis attenuation in man. A V<\/jats:styled-content>1B<\/jats:sub> antagonist is hypothesized as an alcohol\u2010dependent treatment based on the role of the V<\/jats:styled-content>1B<\/jats:sub> receptor in stress regulation and the finding that stress is a trigger for relapse in alcoholics. A V<\/jats:styled-content>1B<\/jats:sub> antagonist has shown favorable effects in rat models of alcohol dependence. A single\u2010dose clinical study was conducted to assess the potential for pharmacokinetic or pharmacodynamic interaction between ABT<\/jats:styled-content>\u2010436 and alcohol.<\/jats:p><\/jats:sec>Methods<\/jats:title>Twenty moderate alcohol drinkers each received the 4 possible combinations of a single 1,000\u00a0mg ABT<\/jats:styled-content>\u2010436 dose (or matching placebo) and a single 0.5\u00a0g\/kg alcohol dose (or placebo for alcohol) in a double\u2010blind, randomized, 4\u2010period crossover study. Plasma ABT<\/jats:styled-content>\u2010436 and blood alcohol levels were measured to assess pharmacokinetic interactions. A computerized cognitive test battery (CDR S<\/jats:styled-content>ystem), B<\/jats:styled-content>ond\u2013L<\/jats:styled-content>ader Visual Analog Scales scales, and a postural stability test were used to measure the effects of alcohol and the potential interaction with ABT<\/jats:styled-content>\u2010436. The pharmacologic effect of ABT<\/jats:styled-content>\u2010436 was assessed by measuring serum cortisol.<\/jats:p><\/jats:sec>Results<\/jats:title>Neither ABT<\/jats:styled-content>\u2010436 nor alcohol affected the blood levels of the other. Alcohol reduced performance on 2 of 5 CDR S<\/jats:styled-content>ystem composite variables (power of attention, p\u00a0<\/jats:italic>=\u00a00.002; quality of secondary episodic memory, p\u00a0<\/jats:italic><\u00a00.001), and decreased postural stability (p\u00a0<\/jats:italic>=\u00a00.043). ABT<\/jats:styled-content>\u2010436 did not exacerbate those deleterious effects. ABT<\/jats:styled-content>\u2010436 reduced serum cortisol (p\u00a0<\/jats:italic><\u00a00.001), and alcohol did not significantly diminish this expected effect on the HPA<\/jats:styled-content> axis.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>No pharmacokinetic or pharmacodynamic interaction between ABT<\/jats:styled-content>\u2010436 and alcohol was observed.<\/jats:p><\/jats:sec>","DOI":"10.1111\/acer.12996","type":"journal-article","created":{"date-parts":[[2016,3,12]],"date-time":"2016-03-12T07:30:41Z","timestamp":1457767841000},"page":"838-845","source":"Crossref","is-referenced-by-count":18,"title":["Single\u2010Dose Interaction Study of the Arginine Vasopressin Type 1B<\/scp> Receptor Antagonist ABT<\/scp>\u2010436 and Alcohol in Moderate Alcohol Drinkers"],"prefix":"10.1111","volume":"40","author":[{"given":"David A.","family":"Katz","sequence":"first","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Locke","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramanuj","family":"Achari","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Wesnes","sequence":"additional","affiliation":[{"name":"Bracket Goring\u2010on\u2010Thames United Kingdom"},{"name":"Department of Psychology Northumbria University Newcastle United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"Tracy","sequence":"additional","affiliation":[{"name":"AbbVie Inc. North Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1974.tb02285.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1037\/0003-066X.41.7.765"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7580.2005.00443.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04812.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2010.00291.x"},{"key":"e_1_2_7_7_1","first-page":"671","article-title":"Impaired water excretion and elevated plasma vasopressin in patients with alcohol\u2010withdrawal symptoms","volume":"64","author":"Emsley RA","year":"1987","journal-title":"Q J Med"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.02.001"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-015-4089-5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.5"},{"key":"e_1_2_7_11_1","first-page":"S89","article-title":"Pharmacokinetics and safety of single ascending doses, food effect and ketoconazole (KTZ) interaction of arginine vasopressin type 1B (V1B) receptor antagonist ABT\u2010436 (Abstract PII\u2010096)","volume":"97","author":"Liu W","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_7_12_1","first-page":"S89","article-title":"Pharmacokinetics (PK) and safety of arginine vasopressin type 1B (V1B) receptor antagonist ABT\u2010436 in healthy volunteers following multiple doses (Abstract PII\u2010098)","volume":"97","author":"Liu W","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00194333"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10253890.2010.512376"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.03.108"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09595230601036960"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00131.x"},{"key":"e_1_2_7_18_1","first-page":"A52","article-title":"The dose and time dependent profile of cognitive impairments of alcohol in young volunteers","volume":"34","author":"Wesnes K","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00236-3"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000533"},{"key":"e_1_2_7_21_1","first-page":"27P","article-title":"A simple mechanical ataxia\u2010meter","volume":"218","author":"Wright BM","year":"1971","journal-title":"J Physiol"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4155\/bio.09.71"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2011.01532.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.05.044"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.97"}],"container-title":["Alcoholism: Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facer.12996","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acer.12996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:49:43Z","timestamp":1696463383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acer.12996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/acer.12996"],"URL":"https:\/\/doi.org\/10.1111\/acer.12996","archive":["Portico"],"relation":{},"ISSN":["0145-6008","1530-0277"],"issn-type":[{"value":"0145-6008","type":"print"},{"value":"1530-0277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}